{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:00:18Z","timestamp":1790222418939,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beyond Air Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-68055-w","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:03:07Z","timestamp":1722038587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A safety evaluation of intermittent high-dose inhaled nitric oxide in viral pneumonia due to COVID-19: a randomised clinical study"],"prefix":"10.1038","volume":"14","author":[{"given":"Talya","family":"Wolak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rokach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shitrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"68055_CR1","doi-asserted-by":"publisher","unstructured":"Ichinose, F., Roberts, J. D. Jr. & Zapol, W. M. Inhaled nitric oxide: A selective pulmonary vasodilator: Current uses and therapeutic potential. Circulation. 109, 3106\u20133111. https:\/\/doi.org\/10.1161\/01.CIR.0000134595.80170.62 (2004).","DOI":"10.1161\/01.CIR.0000134595.80170.62"},{"key":"68055_CR2","doi-asserted-by":"publisher","unstructured":"Rossaint, R., Lewandowski, K. & Zapol, W. M. Our paper 20 years later: Inhaled nitric oxide for the acute respiratory distress syndrome\u2014discovery, current understanding, and focused targets of future applications. Intensive Care Med. 40, 1649\u20131658. https:\/\/doi.org\/10.1007\/s00134-014-3458-6 (2014).","DOI":"10.1007\/s00134-014-3458-6"},{"key":"68055_CR3","doi-asserted-by":"publisher","unstructured":"Adusumilli, N. C., Zhang, D., Friedman, J. M. & Friedman, A. J. Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19. Nitric Oxide. 103, 4\u20138. https:\/\/doi.org\/10.1016\/j.niox.2020.07.003 (2020).","DOI":"10.1016\/j.niox.2020.07.003"},{"key":"68055_CR4","doi-asserted-by":"publisher","unstructured":"Bogdan, C. Nitric oxide and the immune response. Nat. Immunol. 2, 907\u2013916. https:\/\/doi.org\/10.1038\/ni1001-907 (2001).","DOI":"10.1038\/ni1001-907"},{"issue":"10","key":"68055_CR5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nrmicro1004","volume":"2","author":"FC Fang","year":"2004","unstructured":"Fang, F. C. Antimicrobial reactive oxygen and nitrogen species: Concepts and controversies. Nat. Rev. Microbiol. 2(10), 820\u2013832. https:\/\/doi.org\/10.1038\/nrmicro1004 (2004).","journal-title":"Nat. Rev. Microbiol."},{"key":"68055_CR6","doi-asserted-by":"publisher","unstructured":"Hajian, B. et al. Pulmonary vascular effects of pulsed inhaled nitric oxide in COPD patients with pulmonary hypertension. Int. J. Chron. Obstruct. Pulmon Dis. 11, 1533\u20131541. https:\/\/doi.org\/10.2147\/COPD.S106480 (2016).","DOI":"10.2147\/COPD.S106480"},{"key":"68055_CR7","doi-asserted-by":"publisher","unstructured":"Ricciardolo, F. L. Multiple roles of nitric oxide in the airways. Thorax. 58, 175\u2013182. https:\/\/doi.org\/10.1136\/thorax.58.2.175 (2003).","DOI":"10.1136\/thorax.58.2.175"},{"key":"68055_CR8","doi-asserted-by":"publisher","unstructured":"Sorbo, L. D. et al. High doses of inhaled nitric oxide as an innovative antimicrobial strategy for lung infections. Biomedicines. 10, 1525. https:\/\/doi.org\/10.3390\/biomedicines10071525 (2022).","DOI":"10.3390\/biomedicines10071525"},{"key":"68055_CR9","doi-asserted-by":"publisher","unstructured":"Di Fenza, R. et al. High-dose inhaled nitric oxide in acute hypoxemic respiratory failure due to COVID-19: A multicenter phase 2 trial. Am. J. Respir. Crit. Care Med. 208, 1293\u20131304. https:\/\/doi.org\/10.1164\/rccm.202304-0637OC (2023).","DOI":"10.1164\/rccm.202304-0637OC"},{"key":"68055_CR10","doi-asserted-by":"publisher","unstructured":"Flume, P. A. et al. Inhaled nitric oxide for adults with pulmonary non-tuberculous mycobacterial infection. Respir. Med. 206, 107069. https:\/\/doi.org\/10.1016\/j.rmed.2022.107069 (2023).","DOI":"10.1016\/j.rmed.2022.107069"},{"key":"68055_CR11","doi-asserted-by":"publisher","unstructured":"Bentur, L. et al. Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection. J. Cyst. Fibros. 19, 225\u2013231. https:\/\/doi.org\/10.1016\/j.jcf.2019.05.002 (2020).","DOI":"10.1016\/j.jcf.2019.05.002"},{"key":"68055_CR12","doi-asserted-by":"publisher","unstructured":"Akerstr\u00f6m, S. et al. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J. Virol. 79, 1966\u20131969. https:\/\/doi.org\/10.1128\/JVI.79.3.1966-1969.2005 (2005).","DOI":"10.1128\/JVI.79.3.1966-1969.2005"},{"key":"68055_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2009.09.007","volume":"395","author":"S \u00c5kerstr\u00f6m","year":"2009","unstructured":"\u00c5kerstr\u00f6m, S. et al. Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected. Virology. 395, 1\u20139 (2009).","journal-title":"Virology."},{"key":"68055_CR14","doi-asserted-by":"publisher","unstructured":"Garren, M. R. et al. Nitric oxide and viral infection: Recent developments in antiviral therapies and platforms. Appl. Mater Today. 22, 100887. https:\/\/doi.org\/10.1016\/j.apmt.2020.100887 (2021).","DOI":"10.1016\/j.apmt.2020.100887"},{"key":"68055_CR15","doi-asserted-by":"publisher","unstructured":"Hu, Z. et al. Overview of viral pneumonia associated with influenza virus, respiratory syncytial virus, and coronavirus, and therapeutics based on natural products of medicinal plants. Front. Pharmacol. 12: 630834. https:\/\/doi.org\/10.3389\/fphar.2021.630834 (2021).","DOI":"10.3389\/fphar.2021.630834"},{"key":"68055_CR16","doi-asserted-by":"publisher","unstructured":"Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for disease control and prevention. JAMA. 323,1239\u20131242. https:\/\/doi.org\/10.1001\/jama.2020.2648 (2020).","DOI":"10.1001\/jama.2020.2648"},{"key":"68055_CR17","doi-asserted-by":"publisher","unstructured":"Tin Tin Htar, M., Yerramalla, M. S., Mo\u00efsi, J. C. & Swerdlow, D. L. The burden of respiratory syncytial virus in adults: A systematic review and meta-analysis. Epidemiol. Infect. 148: e48. https:\/\/doi.org\/10.1017\/S0950268820000400 (2020).","DOI":"10.1017\/S0950268820000400"},{"key":"68055_CR18","unstructured":"Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD). Preliminary Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States \u2013 2021\u20132022 influenza seasonhttps:\/\/www.cdc.gov\/flu\/about\/burden\/2021-2022.htm#:~:text=The%20overall%20burden%20of%20influenza,flu%20deaths%20 (2022)."},{"key":"68055_CR19","unstructured":"U.S. Food and Drug Administration, The Center for Devices and Radiological Health (CDRH). LungFit\u00ae PH - P200044 https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/lungfit-ph-p200044 (2022)."},{"key":"68055_CR20","unstructured":"European Medicines Agency. INOmax nitric chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.ema.europa.eu\/en\/documents\/overview\/inomax-epar-summary-public_en.pdf (2011)."},{"key":"68055_CR21","doi-asserted-by":"publisher","unstructured":"Valsecchi, C. et al. High-dose inhaled nitric oxide for the treatment of spontaneously breathing pregnant patients with severe coronavirus disease 2019 (COVID-19) Pneumonia. Obstet. Gynecol. 140, 195\u2013203. https:\/\/doi.org\/10.1097\/AOG.0000000000004847 (2022).","DOI":"10.1097\/AOG.0000000000004847"},{"key":"68055_CR22","doi-asserted-by":"publisher","unstructured":"Safaee, F. B. et al. Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia. Nitric Oxide. 11, 7\u201313. https:\/\/doi.org\/10.1016\/j.niox.2021.08.003 (2021).","DOI":"10.1016\/j.niox.2021.08.003"},{"key":"68055_CR23","doi-asserted-by":"publisher","unstructured":"Safaee, F. B. et al. High concentrations of nitric oxide inhalation therapy in pregnant patients with severe coronavirus disease 2019 (COVID-19). Obstet. Gynecol. 136, 1109\u20131113; https:\/\/doi.org\/10.1097\/AOG.0000000000004128 (2020).","DOI":"10.1097\/AOG.0000000000004128"},{"key":"68055_CR24","doi-asserted-by":"publisher","unstructured":"Wiegand, S. B. et al. Rescue treatment with high-dose gaseous nitric oxide in spontaneously breathing patients with severe coronavirus disease 2019. Crit. Care Explor. 2, e0277. https:\/\/doi.org\/10.1097\/CCE.0000000000000277 (2020).","DOI":"10.1097\/CCE.0000000000000277"},{"key":"68055_CR25","doi-asserted-by":"publisher","unstructured":"Kamenshchikov, N. O., Berra, L. & Carroll, R. W. therapeutic effects of inhaled nitric oxide therapy in COVID-19 patients. Biomedicines. 10, 369. https:\/\/doi.org\/10.3390\/biomedicines10020369 (2022).","DOI":"10.3390\/biomedicines10020369"},{"key":"68055_CR26","doi-asserted-by":"publisher","unstructured":"Tal, A. et al. Nitric oxide inhalations in bronchiolitis: A pilot, randomized, double-blinded, controlled trial. Pediatr Pulmonol. 53, 95\u2013102.https:\/\/doi.org\/10.1002\/ppul.23905 (2018).","DOI":"10.1002\/ppul.23905"},{"key":"68055_CR27","doi-asserted-by":"publisher","unstructured":"Goldbart, A. et al. Inhaled nitric oxide therapy in acute bronchiolitis: A multicenter randomized clinical trial [published correction appears in Sci Rep. 2020 Oct 14;10(1):17640]. Sci. Rep. 10, 9605. https:\/\/doi.org\/10.1038\/s41598-020-66433-8 (2020).","DOI":"10.1038\/s41598-020-66433-8"},{"key":"68055_CR28","doi-asserted-by":"publisher","unstructured":"Goldbart, A. et al. Inhaled nitric oxide for the treatment of acute bronchiolitis: A multicenter randomized controlled clinical trial to evaluate dose response. Ann. Am. Thorac. Soc. 20, 236\u2013244. https:\/\/doi.org\/10.1513\/AnnalsATS.202103-348OC (2023).","DOI":"10.1513\/AnnalsATS.202103-348OC"},{"key":"68055_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.niox.2013.03.007","volume":"31","author":"G Regev-Shoshani","year":"2013","unstructured":"Regev-Shoshani, G. et al. Gaseous nitric oxide reduces influenza infectivity in vitro. Nitric Oxide. 31, 48\u201353. https:\/\/doi.org\/10.1016\/j.niox.2013.03.007 (2013).","journal-title":"Nitric Oxide."},{"key":"68055_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101734","volume":"37","author":"D Akaberi","year":"2020","unstructured":"Akaberi, D. et al. Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro. Redox Biol. 37, 101734 (2020).","journal-title":"Redox Biol."},{"key":"68055_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.bbrc.2005.02.085","volume":"329","author":"E Keyaerts","year":"2005","unstructured":"Keyaerts, E. et al. Growth kinetics of SARS-coronavirus in vero E6 cells. Biochem. Biophys. Res. Commun. 329, 1147\u20132115 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"68055_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101826","volume":"39","author":"SB Wiegand","year":"2021","unstructured":"Wiegand, S. B. et al. Antimicrobial effects of nitric oxide in murine models of Klebsiella pneumonia. Redox. Biol. 39, 101826 (2021).","journal-title":"Redox. Biol."},{"key":"68055_CR33","doi-asserted-by":"publisher","unstructured":"Gottlieb, R. L. et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 386, 305\u2013315. https:\/\/doi.org\/10.1056\/NEJMoa2116846 (2022).","DOI":"10.1056\/NEJMoa2116846"},{"key":"68055_CR34","doi-asserted-by":"publisher","unstructured":"Buchanan, J., Li, M., Hendrickson, B., Bhargava, P., & Roychoudhury S. Assessing adverse events in clinical trials during the era of the COVID-19 pandemic. J. Biopharmaceut. Stat. 33, 466\u2013475. https:\/\/doi.org\/10.1080\/10543406.2023.2170398 (2023).","DOI":"10.1080\/10543406.2023.2170398"},{"key":"68055_CR35","unstructured":"Centers for Disease Control and Prevention. Nitrogen Dioxide https:\/\/www.cdc.gov\/niosh\/idlh\/10102440.html (2018)."},{"key":"68055_CR36","doi-asserted-by":"publisher","unstructured":"Mayorga, M.\u00a0Overview of nitrogen dioxide effects on lung with emphasis on military. relevance, Toxicology. 89, 175\u2013192. https:\/\/doi.org\/10.1016\/0300-483x(94)90097-3 (1994).","DOI":"10.1016\/0300-483x(94)90097-3"},{"key":"68055_CR37","doi-asserted-by":"publisher","unstructured":"Lolascon, A. et al. Recommendations for diagnosis and treatment of methemoglobinemia. Am. J. Hematol. 96, 1666\u20131678. https:\/\/doi.org\/10.1002\/ajh.26340 (2021).","DOI":"10.1002\/ajh.26340"},{"key":"68055_CR38","doi-asserted-by":"publisher","unstructured":"Pagliano, P. et al. Characteristics of viral pneumonia in the COVID-19 era: An update.\u00a0Infection. 49, 607\u2013616. https:\/\/doi.org\/10.1007\/s15010-021-01603-y (2021).","DOI":"10.1007\/s15010-021-01603-y"},{"key":"68055_CR39","unstructured":"Freeman, A. M. & Leigh, Jr T. R. Viral Pneumonia. (StatPearls, 2022). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513286\/."},{"key":"68055_CR40","doi-asserted-by":"publisher","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269\u2013271. https:\/\/doi.org\/10.1038\/s41422-020-0282-0 (2020).","DOI":"10.1038\/s41422-020-0282-0"},{"key":"68055_CR41","doi-asserted-by":"publisher","unstructured":"Ader, F. et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): A phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 22, 209\u2013221. https:\/\/doi.org\/10.1016\/S1473-3099(21)00485-0 (2022).","DOI":"10.1016\/S1473-3099(21)00485-0"},{"key":"68055_CR42","doi-asserted-by":"publisher","unstructured":"Srivastava, S., et al. Assessment of nitric oxide (NO) potential to mitigate COVID-19 severity. Virusdisease. 32, 589\u2013594. https:\/\/doi.org\/10.1007\/s13337-021-00702-6 (2021).","DOI":"10.1007\/s13337-021-00702-6"},{"key":"68055_CR43","doi-asserted-by":"publisher","unstructured":"Alqahtani, J. S. et al. Inhaled nitric oxide for clinical management of COVID-19: A systematic review and meta-analysis. Int. J. Environ. Res. Public Health. 19, 12803. https:\/\/doi.org\/10.3390\/ijerph191912803 (2022).","DOI":"10.3390\/ijerph191912803"},{"key":"68055_CR44","doi-asserted-by":"crossref","unstructured":"Nathan, C. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl. Acad. Sci. USA. 97, 8841\u20138848.","DOI":"10.1073\/pnas.97.16.8841"},{"key":"68055_CR45","doi-asserted-by":"publisher","first-page":"2003895","DOI":"10.1002\/advs.202003895","volume":"8","author":"F Lisi","year":"2021","unstructured":"Lisi, F., Zelikin, A. N. & Chandrawati, R. Nitric oxide to fight viral infections. Adv. Sci. 8, 2003895 (2021).","journal-title":"Adv. Sci."},{"key":"68055_CR46","doi-asserted-by":"publisher","unstructured":"Zhao, Y. et al. Inhaled nitric oxide: can it serve as a savior for COVID-19 and related respiratory and cardiovascular diseases? Front. Microbiol. 14, 1277552. https:\/\/doi.org\/10.3389\/fmicb.2023.1277552 (2023).","DOI":"10.3389\/fmicb.2023.1277552"},{"key":"68055_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.7150\/ijms.3880","volume":"9","author":"I Darwish","year":"2012","unstructured":"Darwish, I., Miller, C., Kain, K. C. & Liles, W. C. Inhaled nitric oxide therapy fails to improve outcome in experimental severe influenza. Int. J. Med. Sci. 9, 157\u2013162. https:\/\/doi.org\/10.7150\/ijms.3880 (2012).","journal-title":"Int. J. Med. Sci."},{"key":"68055_CR48","doi-asserted-by":"publisher","unstructured":"Feng, L. et al. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Nat. Commun. 12, 3249. https:\/\/doi.org\/10.1038\/s41467-021-23440-1 (2021).","DOI":"10.1038\/s41467-021-23440-1"},{"key":"68055_CR49","doi-asserted-by":"publisher","unstructured":"Kanda, N. et al. Indirect impact of the COVID-19 pandemic on the incidence of non-COVID-19 infectious diseases: A region-wide, patient-based database study in Japan. Public Health. 214, 20\u201324. https:\/\/doi.org\/10.1016\/j.puhe.2022.10.018 (2023).","DOI":"10.1016\/j.puhe.2022.10.018"},{"key":"68055_CR50","doi-asserted-by":"publisher","unstructured":"Liu, Q., Zhou, Y. H. & Yang, Z. Q. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol. Immunol. 13, 3\u201310. https:\/\/doi.org\/10.1038\/cmi.2015.74 (2016).","DOI":"10.1038\/cmi.2015.74"},{"key":"68055_CR51","doi-asserted-by":"publisher","unstructured":"Ragab, D. et al. The COVID-19 cytokine storm; What we know so far. Front. Immunol. 11, 1446. https:\/\/doi.org\/10.3389\/fimmu.2020.01446 (2020).","DOI":"10.3389\/fimmu.2020.01446"},{"key":"68055_CR52","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/v14051071","volume":"14","author":"C Achangwa","year":"2022","unstructured":"Achangwa, C. et al. Collateral impact of public health and social measures on respiratory virus activity during the COVID-19 pandemic 2020\u20132021. Viruses. 14, 1071. https:\/\/doi.org\/10.3390\/v14051071 (2022).","journal-title":"Viruses."},{"key":"68055_CR53","doi-asserted-by":"publisher","unstructured":"Schulz, K. F., Altman, D. G., Moher, D. & CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. BMJ. 340, c332. https:\/\/doi.org\/10.1136\/bmj.c332 (2010).","DOI":"10.1136\/bmj.c332"},{"key":"68055_CR54","unstructured":"COVID-19 Treatment Guidelines. National Institutes of Health https:\/\/www.covid19treatmentguidelines.nih.gov\/ (2023)."},{"issue":"3","key":"68055_CR55","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/cid\/ciq076","volume":"52","author":"SR Majumdar","year":"2011","unstructured":"Majumdar, S. R., Eurich, D. T., Gamble, J. M., Senthilselvan, A. & Marrie, T. J. Oxygen saturations less than 92% are associated with major adverse events in outpatients with pneumonia: A population-based cohort study. Clin. Infect. Dis. 52(3), 325\u2013331. https:\/\/doi.org\/10.1093\/cid\/ciq076 (2011).","journal-title":"Clin. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68055-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68055-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68055-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:15:10Z","timestamp":1722039310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68055-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68055"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68055-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Because of the perception of a conflict of interest and in the interest of full transparency, we are disclosing the relationships between Profs. Talya Wolak, Asher Tal, Alon Grossman and Dr. Dror Dicker and Beyond Air Inc. All four authors have signed contracts with the company. Prof Wolak received payment including traveling fees for attending a conference and all payments were made through her affiliated institution. Prof. Tal bought stocks, received a stock option grant, and consulting fees. Drs. Dicker and Grossman received payment through their affiliated institutions.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17201"}}